Psychedelic therapies are becoming mainstream. Deutsche Bank thinks this drug developer could triple
Published on 30/03/2026 10:29 AM
Psychedelic therapies are becoming mainstream. Deutsche Bank thinks this drug developer could tripleDeutsche Bank backs AtaiBeckley in the Psychedelic Renaissance, citing drugs BPL-003, VLS-01 and EMP-01 and projecting multibillion dollar sales after FDA approval.By CNBC Pro | Davis Giangiulio March 30, 2026, 10:29:34 AM IST (Published)Deutsche Bank believes AtaiBeckley is well-positioned to be a winner in the "Psychedelic Renaissance."Continue Reading with CNBC-TV18 Access MembershipPriority Access and Networking: CNBC-TV18's flagship events Interaction with CNBC-TV18's journalists Webinars & LIVE Q&As with India Inc. Leaders Exclusive CNBC-TV18 studio & newsroom tours Premium business insights, expert opinions & analysis Curated lifestyle privileges & offers